The trend of adjusted means of CVD risk factors in participants during the follow up.

<p>The follow up period of Tehran Lipid and Glucose Study included Phase 2 (2002–2005), Phase 3 (2005–2008), Phase 4 (2008–2011) and Phase 5 (2011–2014).</p

Baseline characteristics of respondents and non-respondents participants.

<p>Baseline characteristics of respondents and non-respondents participants.</p

Adjusted prevalence of CVD risk factors in participants with prevalent CVD in each phase; Tehran Lipid and Glucose Study.

<p>Adjusted prevalence of CVD risk factors in participants with prevalent CVD in each phase; Tehran Lipid and Glucose Study.</p

Multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) of potential cardiovascular risk factors for incident CVD and all-cause mortality, without obesity mediators controlling for general adiposity status, Tehran lipid and Glucose study (1999–2012)

<p>Multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) of potential cardiovascular risk factors for incident CVD and all-cause mortality, without obesity mediators controlling for general adiposity status, Tehran lipid and Glucose study (1999–2012)</p

Multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) of potential cardiovascular risk factors for incident CVD and all-cause mortality, with obesity mediators (diabetes, hypertension, lipid profile and CKD), controlling for general adiposity status, Tehran lipid and Glucose study (1999–2012)

<p>Multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) of potential cardiovascular risk factors for incident CVD and all-cause mortality, with obesity mediators (diabetes, hypertension, lipid profile and CKD), controlling for general adiposity status, Tehran lipid and Glucose study (1999–2012)</p

Baseline characteristics^* of respondent and non-respondent participants in both genders; Tehran Lipid and Glucose Study 1999–2005.

<p>Baseline characteristics^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0167623#t002fn001" target="_blank">*</a>} of respondent and non-respondent participants in both genders; Tehran Lipid and Glucose Study 1999–2005.</p

Age-adjusted mean levels of cardiovascular risk factors in each phase in male subjects.

<p>Mean levels of cardiovascular risk factors of diabetic and non-diabetic participants was calculated separately with adjustment of related participants' age in each phase while the interaction of diabetes status was assessed in a pooled model consisting both diabetic and non- diabetic participants. Black circles  =  diabetic group; white circles  =  non diabetic group; DM, diabetes mellitus; WHR, waist to hip ratio; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TGs, triglycerides; FPG, fasting plasma glucose; TC, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol.</p

Baseline characteristics of participants by gender and diabetes status^a; Teheran Lipid and Glucose Study (March 1999- December 2011).

a<p>values are presented as mean (SD) unless otherwise indicated</p>b<p>presented as median (interquartile range).</p><p>FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; TGs, triglycerides; TC, total cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.</p><p>Baseline characteristics of participants by gender and diabetes status^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0112639#nt101" target="_blank">a</a>}; Teheran Lipid and Glucose Study (March 1999- December 2011).</p

Clinical characteristics of patients included in the study based on antiviral treatment and incidence of acute kidney injury.

Clinical characteristics of patients included in the study based on antiviral treatment and incidence of acute kidney injury.</p

Logistic regression and odds ratio for different category of antiviral treatment and incidence of acute kidney injury and mortality, intensive care unit admission and prolonged hospitalization.

Logistic regression and odds ratio for different category of antiviral treatment and incidence of acute kidney injury and mortality, intensive care unit admission and prolonged hospitalization.</p